🚀 VC round data is live in beta, check it out!
BioMarin Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioMarin Pharmaceutical and similar public comparables like Cipla, Zydus Lifesciences, RemeGen, Dr Reddy's Laboratories and more.
BioMarin Pharmaceutical Overview
About BioMarin Pharmaceutical
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
Founded
1996
HQ
Employees
3.2K
Website
Sectors
Financials (LTM)
EV
$10B
BioMarin Pharmaceutical Financials
BioMarin Pharmaceutical reported last 12-month revenue of $3B and EBITDA of $705M.
In the same LTM period, BioMarin Pharmaceutical generated $3B in gross profit, $705M in EBITDA, and $496M in net income.
Revenue (LTM)
BioMarin Pharmaceutical P&L
In the most recent fiscal year, BioMarin Pharmaceutical reported revenue of $3B and EBITDA of $573M.
BioMarin Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 79% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | $705M | XXX | $573M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 18% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $496M | XXX | $349M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 11% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioMarin Pharmaceutical Stock Performance
BioMarin Pharmaceutical has current market cap of $11B, and enterprise value of $10B.
Market Cap Evolution
BioMarin Pharmaceutical's stock price is $54.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $10B | $11B | 1.0% | XXX | XXX | XXX | $1.81 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioMarin Pharmaceutical Valuation Multiples
BioMarin Pharmaceutical trades at 2.9x EV/Revenue multiple, and 13.6x EV/EBITDA.
EV / Revenue (LTM)
BioMarin Pharmaceutical Financial Valuation Multiples
As of April 18, 2026, BioMarin Pharmaceutical has market cap of $11B and EV of $10B.
Equity research analysts estimate BioMarin Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioMarin Pharmaceutical has a P/E ratio of 21.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV (current) | $10B | XXX | $10B | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.6x | XXX | 16.7x | XXX | XXX | XXX |
| EV/EBIT | 16.0x | XXX | 23.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 21.2x | XXX | 30.1x | XXX | XXX | XXX |
| EV/FCF | 11.5x | XXX | 13.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioMarin Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioMarin Pharmaceutical Margins & Growth Rates
BioMarin Pharmaceutical's revenue in the last 12 month grew by 12%.
BioMarin Pharmaceutical's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.
BioMarin Pharmaceutical's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioMarin Pharmaceutical's rule of X is 61% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioMarin Pharmaceutical Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 18% | XXX | XXX | XXX |
| EBITDA Growth | 66% | XXX | 92% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 19% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 25% | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioMarin Pharmaceutical Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BioMarin Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Cipla | XXX | XXX | XXX | XXX | XXX | XXX |
| Zydus Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| RemeGen | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr Reddy's Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Samsung Bioepis | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioMarin Pharmaceutical M&A Activity
BioMarin Pharmaceutical acquired XXX companies to date.
Last acquisition by BioMarin Pharmaceutical was on XXXXXXXX, XXXXX. BioMarin Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioMarin Pharmaceutical
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioMarin Pharmaceutical Investment Activity
BioMarin Pharmaceutical invested in XXX companies to date.
BioMarin Pharmaceutical made its latest investment on XXXXXXXX, XXXXX. BioMarin Pharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioMarin Pharmaceutical
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioMarin Pharmaceutical
| When was BioMarin Pharmaceutical founded? | BioMarin Pharmaceutical was founded in 1996. |
| Where is BioMarin Pharmaceutical headquartered? | BioMarin Pharmaceutical is headquartered in United States. |
| How many employees does BioMarin Pharmaceutical have? | As of today, BioMarin Pharmaceutical has over 3K employees. |
| Who is the CEO of BioMarin Pharmaceutical? | BioMarin Pharmaceutical's CEO is Alexander Hardy. |
| Is BioMarin Pharmaceutical publicly listed? | Yes, BioMarin Pharmaceutical is a public company listed on Nasdaq. |
| What is the stock symbol of BioMarin Pharmaceutical? | BioMarin Pharmaceutical trades under BMRN ticker. |
| When did BioMarin Pharmaceutical go public? | BioMarin Pharmaceutical went public in 1999. |
| Who are competitors of BioMarin Pharmaceutical? | BioMarin Pharmaceutical main competitors are Cipla, Zydus Lifesciences, RemeGen, Dr Reddy's Laboratories. |
| What is the current market cap of BioMarin Pharmaceutical? | BioMarin Pharmaceutical's current market cap is $11B. |
| What is the current revenue of BioMarin Pharmaceutical? | BioMarin Pharmaceutical's last 12 months revenue is $3B. |
| What is the current revenue growth of BioMarin Pharmaceutical? | BioMarin Pharmaceutical revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of BioMarin Pharmaceutical? | Current revenue multiple of BioMarin Pharmaceutical is 2.9x. |
| Is BioMarin Pharmaceutical profitable? | Yes, BioMarin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioMarin Pharmaceutical? | BioMarin Pharmaceutical's last 12 months EBITDA is $705M. |
| What is BioMarin Pharmaceutical's EBITDA margin? | BioMarin Pharmaceutical's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of BioMarin Pharmaceutical? | Current EBITDA multiple of BioMarin Pharmaceutical is 13.6x. |
| What is the current FCF of BioMarin Pharmaceutical? | BioMarin Pharmaceutical's last 12 months FCF is $827M. |
| What is BioMarin Pharmaceutical's FCF margin? | BioMarin Pharmaceutical's last 12 months FCF margin is 25%. |
| What is the current EV/FCF multiple of BioMarin Pharmaceutical? | Current FCF multiple of BioMarin Pharmaceutical is 11.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.